AKBA Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypo…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ... Akebia Therapeutics Inc (AKBA) reports strong Vafseo growth with over 10,500 patients, while navigating Erixia declines and planning strategic price adjustments for 2027. | ||
 Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +33.33% and -5.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Akebia Therapeutics Q2 Earnings Call Highlights Akebia Therapeutics (NASDAQ:AKBA) reported second-quarter revenue growth for its Vafseo anemia treatment while highlighting an interim clinical result from the VOICE study and progress across its kidney disease pipeline. Vafseo net product revenue reached $21.3 million in the second quarter of 2026 | ||